Subscribe To
OPT / Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference

Content Topics
Opthea
Present
Eyecelerator
Forum
2023
American
Academy
Ophthalmology
Conference
Stock
OPT
OPT News

By GlobeNewsWire
October 30, 2023
Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference
MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing no more_horizontal

By GlobeNewsWire
July 24, 2023
Opthea to Present at the 2023 Ophthalmology Innovation Summit
MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing no more_horizontal

By GlobeNewsWire
May 8, 2023
Opthea To Present at the JMP Securities Life Sciences Conference
MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing nov more_horizontal

By GlobeNewsWire
January 30, 2023
Opthea To Present at Sequire Biotechnology Conference
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing no more_horizontal

By GlobeNewsWire
December 12, 2022
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing no more_horizontal

By GlobeNewsWire
December 6, 2022
Opthea to Present at the FLORetina 2022 Congress
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing no more_horizontal

By Seeking Alpha
November 12, 2022
Optiva Inc. (RKNEF) Q3 2022 Earnings Call Transcript
Optiva Inc. (OTCPK:RKNEF) Q3 2022 Results Conference Call November 9, 2022 8:30 AM ET Company Participants Ali Mahdavi - Investor Relations John Giere more_horizontal